North Star Asset Management Inc. Increases Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

North Star Asset Management Inc. lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 55,625 shares of the medical research company's stock after acquiring an additional 1,581 shares during the period. Thermo Fisher Scientific comprises approximately 1.3% of North Star Asset Management Inc.'s holdings, making the stock its 20th largest position. North Star Asset Management Inc.'s holdings in Thermo Fisher Scientific were worth $28,938,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. GF Fund Management CO. LTD. bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at approximately $4,930,000. University of Texas Texas AM Investment Management Co. raised its stake in shares of Thermo Fisher Scientific by 339.7% during the fourth quarter. University of Texas Texas AM Investment Management Co. now owns 1,662 shares of the medical research company's stock worth $865,000 after buying an additional 1,284 shares during the last quarter. Parr Mcknight Wealth Management Group LLC bought a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $262,000. Pacific Point Advisors LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $455,000. Finally, Vega Investment Solutions acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at about $530,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on TMO. Raymond James restated an "outperform" rating and set a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, May 21st. Wells Fargo & Company reduced their price target on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a research report on Thursday, April 24th. Morgan Stanley raised their price objective on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research note on Friday, January 31st. Finally, Barclays cut their target price on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Four equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and an average target price of $607.43.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now owns 23,167 shares in the company, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the sale, the chief executive officer now directly owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. This represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 14,075 shares of company stock valued at $7,305,942 in the last 90 days. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of TMO stock traded up $2.08 during trading hours on Thursday, hitting $404.21. 1,191,604 shares of the company's stock were exchanged, compared to its average volume of 1,872,361. The firm has a market cap of $152.59 billion, a P/E ratio of 24.45, a P/E/G ratio of 2.99 and a beta of 0.82. The firm has a 50 day moving average of $435.42 and a two-hundred day moving average of $502.00. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a fifty-two week low of $390.50 and a fifty-two week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business's revenue for the quarter was up .2% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.11 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.